ADC Consulting- With knowledge of the latest industry trends, I have extensive experience in antibody drug conjugate (ADC) technology, including novel drug linker screening, analytical testing methods, bi-functional ADC constructs, bioconjugation process development and manufacturing scale-up. My last 8 years at Abbvie/Abbott has given me great experience with two drugs in humans trials, including StemCentrx ADC process development work. I managed the entire bioconjugation lab in Redwood City. Prior to Abbvie, I conjugated with the Mylotarg pioneers at Coulter Pharmaceuticals in 1999, then moved to Eos Biotechnology, were we had one of the first ADC development contracts with Seattle Genetics. Eos was acquired by Protein Design Labs, which eventually was acquired by Abbott/Abbvie. I am currently consulting to select clients, and was an invited expert speaker at the World ADC San Diego 2018 conference, and will be speaking again in Shanghai, China for WADC 2019, as well as the London WADC 2020.